BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Decitabine/cedazuridine (Inqovi) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Decitabine/cedazuridine (Inqovi)\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04953897-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 1 readout est. (NCT04953897
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 1\, Acute Myeloid Leuk
 emia.\nStudy: Study to Evaluate the Pharmacokinetics and Safety of Oral De
 citabine and Cedazuridine in Cancer Patients With Renal Impairment\nEstima
 ted primary completion: December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04953897
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04953910-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 1 readout est. (NCT04953910
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 1\, Acute Myeloid Leuk
 emia.\nStudy: Study to Evaluate the Pharmacokinetics and Safety of Oral De
 citabine and Cedazuridine in Cancer Patients With Hepatic Impairment\nEsti
 mated primary completion: December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04953910
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06802146-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 1 readout est. (NCT06802146
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 1.\nStudy: Early Inter
 vention in High Risk CCUS\nEstimated primary completion: 1 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/decitabine-cedazuridi
 ne-inqovi#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06802146
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05360160-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 1/2 readout est. (NCT053601
 60)
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 1/2\, Acute Myeloid Le
 ukemia.\nStudy: A Phase I-II Study Investigating the All-Oral Combination 
 of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) an
 d Venetoclax in Acute Myeloid Leukemia (SAVE)\nEstimated primary completio
 n: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 ecitabine-cedazuridine-inqovi#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05360160
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03922555-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 1 readout est. (NCT03922555
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 1.\nStudy: ASTX727 in 
 Recurrent/Progressive Non-enhancing IDH Mutant Gliomas\nEstimated primary 
 completion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/decitabine-cedazuridine-inqovi#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03922555
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04872543-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 2 readout est. (NCT04872543
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 2.\nStudy: A Study of 
 ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)\nE
 stimated primary completion: April 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04872543
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05178693-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 1 readout est. (NCT05178693
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 1.\nStudy: Lutathera a
 nd ASTX727 in Neuroendocrine Tumours\nEstimated primary completion: 30 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/decitabine-ced
 azuridine-inqovi#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05178693
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05272384-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20270628
DTEND;VALUE=DATE:20270629
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 1 readout est. (NCT05272384
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 1.\nStudy: Testing the
  Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Ly
 mphoma\nEstimated primary completion: 28 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05272384
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04061421-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 1/2 readout est. (NCT040614
 21)
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 1/2.\nStudy: Active My
 eloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Sy
 ndromes (ABNL-MARRO)\nEstimated primary completion: August 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT040
 61421
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05600894-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 2 readout est. (NCT05600894
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 2.\nStudy: Venetoclax 
 in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Le
 ukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm\nEst
 imated primary completion: 31 August 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05600894
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04093570-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 2 readout est. (NCT04093570
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 2\, Acute Myeloid Leuk
 emia.\nStudy: A Study for Participants Who Participated in Prior Clinical 
 Studies of ASTX727 (Standard Dose)\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/decitabine-
 cedazuridine-inqovi#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04093570
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06661915-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 2 readout est. (NCT06661915
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 2.\nStudy: A Randomize
 d Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferat
 ive Neoplasms (MPNs)\nEstimated primary completion: 31 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/decitabine-cedazuridine-i
 nqovi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06661915
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05010122-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 1/2 readout est. (NCT050101
 22)
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 1/2\, Acute Myeloid Le
 ukemia.\nStudy: ASTX727\, Venetoclax\, and Gilteritinib for the Treatment 
 of Newly Diagnosed\, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leu
 kemia or High-Risk Myelodysplastic Syndrome\nEstimated primary completion:
  30 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dec
 itabine-cedazuridine-inqovi#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05010122
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06177171-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 1 readout est. (NCT06177171
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 1.\nStudy: Olaparib an
 d ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated
  Tumors\nEstimated primary completion: 31 January 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06177171
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05201066-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20280214
DTEND;VALUE=DATE:20280215
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 2 readout est. (NCT05201066
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 2\, Myelodysplastic Sy
 ndromes.\nStudy: Roll-over Study for Patients Who Have Completed a Prior N
 ovartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investi
 gator to Benefit From Continued Treatment With Sabatolimab.\nEstimated pri
 mary completion: 14 February 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05201066
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06484062-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 1 readout est. (NCT06484062
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 1\, Acute Myeloid Leuk
 emia.\nStudy: Testing the Anti-cancer Drug\, Cirtuvivint\, and Its Combina
 tion With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leuke
 mia and Myelodysplastic Syndromes\nEstimated primary completion: 1 June 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/decitabine-cedazu
 ridine-inqovi#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06484062
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05960773-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 2 readout est. (NCT05960773
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 2.\nStudy: Decitabine/
 Cedazuridine (INQOVI)\, an Oral DNA Demethylating Agent\, in Subjects With
  BAP1 Cancer Predisposition Syndrome and Subclinical\, Early-Stage Mesothe
 lioma\nEstimated primary completion: 1 July 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05960773
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04655755-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20280720
DTEND;VALUE=DATE:20280721
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 1/2 readout est. (NCT046557
 55)
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 1/2.\nStudy: Venetocla
 x in Combination With ASTX727 for the Treatment of Treatment-Naive High-Ri
 sk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia\nEstimated 
 primary completion: 20 July 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04655755
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05007873-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 2 readout est. (NCT05007873
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 2.\nStudy: ASTX727 and
  Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or
  BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase\nEstimated pri
 mary completion: 30 October 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05007873
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04746235-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 2 readout est. (NCT04746235
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 2\, Acute Myeloid Leuk
 emia.\nStudy: Venetoclax and ASTX727 for the Treatment of Relapsed\, Refra
 ctory\, or Newly Diagnosed Acute Myeloid Leukemia\nEstimated primary compl
 etion: 31 October 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/decitabine-cedazuridine-inqovi#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04746235
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191978-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 1 readout est. (NCT06191978
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 1\, Acute Myeloid Leuk
 emia.\nStudy: A Phase Ia/Ib Open-label\, Multiple Dose\, Study to Determin
 e the Recommended Dose\, Evaluate PKs\, PDs\, Safety\, and Activity of Ven
 etoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pedi
 atric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)\nEsti
 mated primary completion: 31 December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06191978
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153497-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20300426
DTEND;VALUE=DATE:20300427
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 2 readout est. (NCT07153497
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 2\, Acute Myeloid Leuk
 emia.\nStudy: Testing the Use of an IDH1 Inhibitor\, Olutasidenib\, in Acu
 te Myeloid Leukemia Added to ASTX727 and Venetoclax\; in High-Risk MDS Add
 ed to ASTX727\; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy
 )\nEstimated primary completion: 26 April 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07153497
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472322-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 1/2 readout est. (NCT074723
 22)
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 1/2.\nStudy: ASTX727 &
  Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(
 L)1\nEstimated primary completion: May 2031. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07472322
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04742634-2362@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20331130
DTEND;VALUE=DATE:20331201
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 1/2 readout est. (NCT047426
 34)
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 1/2\, Myelodysplastic 
 Syndromes.\nStudy: Pre-emptive Therapy With DEC-C to Improve Outcomes in M
 DS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic
  Cell Transplant\nEstimated primary completion: 30 November 2033. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/decitabine-cedazuridine-inqov
 i#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 742634
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
